Our work has shown a subset of melanoma cells to secrete transforming growth factor-beta (TGF-β) in response to vemurafenib treatment, and this TGF-β, in turn, activates dermal fibroblasts that then express alpha-smooth muscle actin, produce fibronectin and secrete neuregulin (NRG-1) [5]. The gene discussed is TGFB1; the disease is melanoma.